Enzon Pharmaceuticals (ENZN)
Your Dashboard
Displaying ENZN Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 1.898M
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.1124
- Beneish M-Score Pro
- Beta Pro
- Book Value 197.15M
- Book Value per Share 4.082
- Capital Expenditures 0.00
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing -3.848M
- Cash Financing TTM -83.35M
- Cash Investing -53.77M
- Cash Investing TTM -226.11M
- Cash Operations -0.496M
- Cash Operations TTM -14.27M
- Cash and Equivalents 46.21M
- Cash and ST Investments 124.69M
- Current Ratio 9.803
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.6378
- Dividend
- Dividend Yield 0.00%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share -0.02
- Earnings Per Share Growth
- Earnings Per Share TTM -0.43
- Earnings Yield -6.80%
- Effective Tax Rate TTM Pro
- Enterprise Value 384.73M
- Expenses 11.67M
- Expenses TTM 62.92M
- Free Cash Flow -0.496M
- Free Cash Flow TTM -14.80M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM 40.65M
- Income from Cont. Ops Pro
- Interest Expense 1.417M
- Interest Income 0.478M
- Inventories
- KZ Index Pro
- Liabilities 139.80M
- Long Term Debt 125.75M
- Market Cap 305.19M
- Net Income -1.071M
- Net Income TTM -22.26M
- Net PP&E 15.51M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price 6.32
- Price / Book Value 1.548
- Price / Sales Ratio 7.508
- Price / Tangible Book Value Pro
- Profit Margin -10.10%
- R&D Expense 6.999M
- Receivables Turnover
- Retained Earnings -146.14M
- Retained Earnings Growth
- Return on Assets -5.97%
- Return on Equity -9.91%
- Return on Invested Capital Pro
- Revenue Growth -41.18%
- Revenue Per Share TTM 0.8418
- Revenues 10.60M
- Revenues TTM 40.65M
- SG&A Expense 3.675M
- Shareholders Equity 197.15M
- Shares Outstanding 48.29M
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 336.95M
- Total Return Price 6.32
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these ENZN related companies
ENZN News
$ENZN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3FPH
about 53 days ago by MarketBrief
about 53 days ago by MarketBrief
Icahn Capital's George Hebard Named as Director on Enzon Pharma (ENZN) Board
Feb 28, 5:17PM Street Insider
Feb 28, 5:17PM Street Insider
@TER_Intraday nice Fry Pan bottom in $ENZN since early Dec. Thanks for that.
about 123 days ago by 1nvestor
about 123 days ago by 1nvestor
EBR: Watchlist/worksheet/3Trading Ideas: $POT $IACI $ENZN http://stks.co/27m6
about 123 days ago by TER_Intraday
about 123 days ago by TER_Intraday
$ENZN http://stks.co/1VXa Biotech name. Flagging right under the 50MA. Watch the $7.15 level.
about 168 days ago by VexTrades
about 168 days ago by VexTrades
Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer
Dec 08, 6:15PM Marketwire
Dec 08, 6:15PM Marketwire
$ENZN http://stks.co/1Q88 Long setup for a short term trade. Tight price action in small wedge after recent strong buy volume
about 174 days ago by ToddinFL
about 174 days ago by ToddinFL
$ENZN http://stks.co/1ONJ Heavy short interest may have been taken out last week. Seth Klarman & Carl Icahn own 30% of shares.
about 175 days ago by drdebt
about 175 days ago by drdebt
Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting
Nov 12, 1:00PM Marketwire
Nov 12, 1:00PM Marketwire
Enzon COO Ralph Del Campo steps down, CFO Ana I. Stancic promoted to COO
Oct 17, 4:25PM FlyOnTheWall
Oct 17, 4:25PM FlyOnTheWall
Enzon Pharma (ENZN) Promotes CFO Stancic to COO; Forms Special Committee
Oct 17, 4:14PM Street Insider
Oct 17, 4:14PM Street Insider
Enzon Announces Promotion of CFO Ana I. Stancic to COO; Continues to Serve as CFO
Oct 17, 4:14PM Benzinga
Oct 17, 4:14PM Benzinga
Iridian Asset Management Raises Stake in Enzon Pharmaceuticals, Inc. (ENZN) to 11.6%
Oct 06, 1:47PM Street Insider
Oct 06, 1:47PM Street Insider
Enzon $ENZN to Cut Workforce by 48% to Support R&D Activities, Sees Q3 Charge ~$3M
about 249 days ago by Street_Insider
about 249 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ENZN | 6.32 | +0.16 | +2.60% | 305.19M |
| DWSN | 24.95 | +0.07 | +0.28% | 197.60M |
| DWRI | None | None | None | |
| DWM | 39.25 | -0.11 | -0.27% | |
| DWCH | 12.06 | -0.17 | -1.39% | 75.25M |
| DWA | 17.85 | +0.13 | +0.73% | 1.500B |
| DW | 26.41 | -0.21 | -0.79% | 587.36M |
| DVY | 54.98 | -0.09 | -0.16% | |
| DVOX | 1.51 | +0.00 | +0.00% | 15.89M |
| DVN | 60.02 | -0.41 | -0.68% | 24.25B |
